Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes
NCT02455076 on ClinicalTrials.gov · last registry update 2019-06-20
An unusually large phase 4: 150 participants, more than double the 75 typical for the stage. The sponsor logged completion for March 2018. Primary outcome, as filed: Mean Daily Blood Glucose Concentration Inpatient. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Emory University
- Sponsor type
- Other
- Enrollment
- 150
- Started
- 2015-09
- Primary completion
- 2018-03 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Mean Daily Blood Glucose Concentration Inpatient
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.